Teva Closes Emalex Biosciences Acquisition, Strengthens Neuroscience Pipeline

Teva Pharmaceutical completed its acquisition of Emalex Biosciences, adding ecopipam to its late-stage neuroscience pipeline. Phase 3 data were published in JAMA Neurology with U.S. NDA submission expected in H2 2026. The acquisition has minimal direct forex impact as it's a routine pharmaceutical deal without major financial disclosures. USD pairs may see negligible movement from broader healthcare sector sentiment.